Eisai Forecasts 63% Leqembi Revenue Surge to ¥143.5B in FY2026
Event summary
- Eisai projects Leqembi revenue to reach ¥143.5B (SEK 8.4B) in FY2026, a 63% YoY increase.
- BioArctic stands to earn approximately SEK 880M in royalties from Leqembi sales.
- Leqembi is approved in 53 countries with regulatory reviews ongoing in 6 more.
- Eisai and BioArctic are preparing for joint commercialization in the Nordic region.
- Leqembi's subcutaneous formulation is under priority review in both the US and China.
The big picture
Eisai's aggressive revenue forecast for Leqembi underscores the growing market for Alzheimer's disease treatments. The 63% projected growth reflects both expanding approvals and increasing adoption of the drug. BioArctic's royalty income highlights the value of its long-standing collaboration with Eisai, while the joint commercialization efforts in the Nordic region signal a strategic push into new markets. The drug's regulatory progress in major markets like the US and China will be critical in sustaining this momentum.
What we're watching
- Regulatory Momentum
- The pace at which Leqembi gains approvals in additional countries will determine its global market penetration.
- Commercial Execution
- Whether Eisai and BioArctic can successfully launch Leqembi in the Nordic region will test their commercialization capabilities.
- Pipeline Development
- How BioArctic's other neurodegenerative disease projects progress could diversify its revenue streams beyond Leqembi.
Related topics